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1. Introduction 
Acute coronary syndrome (ACS), i.e. acute myocardial infarction (MI) and unstable angina, 
is a life threatening disease, and its treatment after onset has greatly improved; however, we 
are not satisfied with the long-term outcome of the patients with ACS. Furthermore, we 
cannot adequately prevent the onset of ACS, although we know many risk factors of ACS, 
e.g. diabetes mellitus, dyslipidemia, hypertension, obesity, and smoking. 
As plaque disruption and thrombosis is known as the major cause of ACS, many 
investigations to identify vulnerable plaques that are prone to disrupt have been performed 
but failed to identify high-risk lesions of future ACS event. Major reason for this failure may 
be that disruption of plaques does not always cause ACS and probably very few percentages 
of disrupted plaques may actually cause ACS. In order to know adequately about the 
mechanisms for the onset of ACS and to prevent it effectively, we have to clarify those 
missing factors that are essential for the disrupted plaques to cause ACS. 
In this chapter, we would like to elucidate and discuss on the known and unknown 
mechanisms for the onset of ACS from the angioscopic point of view. 
2. Culprit lesions of acute coronary syndrome 
The culprit lesions of ACS1, 2 have disrupted yellow plaque and thrombus in >90% of cases. 
The surface of the yellow plaques is irregular and has the adhesion of white or mixed 
thrombus. The plaque is defined as ruptured3, 4 if the protrusion of yellow necrotic core is 
observed; otherwise, it is defined as eroded (or non-ruptured). Thrombus2 directly adhering 
to the plaque surface is usually white, and it becomes reddish when blood flow is disturbed 
by massive white thrombus and the fibrin network captures many red blood cells in it, i.e. 
mixed or red thrombus. In the same way, thrombus becomes yellow when the fibrin 
network of white thrombus contains protruded necrotic core, i.e. yellow thrombus. 
After reperfusion therapy1 or coronary intervention with balloon or stent, the culprit lesion 
of ACS gradually loses its thrombogenicity. In the patients with acute MI, 64% of patients 
still have thrombus at their culprit lesion at one month after reperfusion, while it becomes as 
low as 5% at 6 months. The prevalence of thrombus at one month is higher in the patients 
with diabetic patients than in the non-diabetic patients (78% vs. 45%), suggesting that the 
healing process of disrupted plaque is deteriorated in the diabetic patients. 
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As >90% of ACS patients have disrupted yellow plaque in their culprit lesions, both 
ruptured and eroded plaques, which are detected in about 70% and 30% of cases, 
respectively, by pathologic studies, should be detected as yellow plaques5. We have recently 
revealed4 that both ruptured and non-ruptured yellow plaques detected by angioscopy have 
similar atherosclerotic characteristics including thin-cap fibroatheroma (TCFA) when 
examined by VH-IVUS (Figure 1). 
3. Detection of vulnerable plaques by angioscopy 
Because the majority of ACS culprit lesions have disrupted yellow plaques, yellow plaques 
should be the vulnerable plaques that are prone to disrupt. Yellow plaques are classified 
into 3 grades6 according to its yellow color intensity: grade 1, slight yellow; grade 2, yellow; 
and grade 3, intensive yellow (Figure 2). We have revealed that yellow plaques of higher 
yellow color grade have the higher incidence of having thrombus on it, i.e. higher incidence 
of disruption, suggesting that those plaques are more vulnerable. Furthermore, the yellow 
plaques of higher yellow color grade have the higher incidence of positive remodeling and 
the thinner fibrous cap7, which supports the idea that those yellow plaques are more 
vulnerable. 
Although we have experienced >5,000 cases of angioscopic examinations and found huge 
number of yellow plaques, it was quite rare that the plaque caused ACS shortly after the 
examination. However, the prospective follow-up of the angioscopically examined patients 
have revealed8 that patients with more than 2 yellow plaques per vessel have the higher 
incidence of ACS event than the patients with 1 or no yellow plaque per vessel during the 
mean follow-up interval of 4.8 years. Formation of yellow plaques occurs equally in the 
culprit and non-culprit vessels of MI as it is regarded pan-coronary process of 
atherosclerosis progression9 (Figure 3). Therefore, the patients who have many yellow 
plaques in their coronary arteries are regarded as vulnerable patients. Judging from the 
results of this and other angioscopic studies, the probability of each yellow plaque to disrupt 
and to cause ACS may be estimated5 as 25%/year and 0.3-1%/year, respectively.  
4. Silent plaque disruption and missing factors for the onset of acute 
coronary syndrome 
Disrupted yellow plaques are sometimes found in the asymptomatic patients or in the non-
culprit segments of ACS patients, which are called silent plaque disruptions10, 11. Factors 
required for the disrupted plaques to cause symptomatic ACS are unknown, which is an 
important but unsolved issue for clarifying the mechanism of ACS onset. However, 
thrombogenic potential of blood, thrombogenic potential of necrotic core that would be 
exposed to blood by plaque rupture, underlying stenosis or stenosis caused by the 
protrusion of necrotic core at the site of plaque rupture, and/or vasoconstriction may play a 
role for the onset of ACS after the disruption of vulnerable plaques12. Investigations to 
clarify the contributions of these or other factors have not been reported adequately. 
Although the thrombogenicity of blood, i.e. vulnerable blood, has been regarded one of 
important factors, reports on this issue are limited. We have recently reported13 that 
originally defined parameter of blood thrombogenicity (blood vulnerability index) is 
significantly and extremely higher in the patients with acute MI than in the patients with 
stable coronary heart disease. 
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Most of ACS culprit lesions have disrupted yellow plaque, which is classified into ruptured or non-
ruptured yellow plaque by angioscopy.  Non-rupture would include small rupture and erosion of 
pathologic classifications.  Both of ruptured and non-ruptured yellow plaques have similar 
atherosclerotic characteristics by VH-IVUS.  (From reference #4) 
Fig. 1. Culprit lesions of ACS 
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Yellow plaques are classified into 3 grades according to these standard colors: grade 1, slight yellow; grade 2, 
yellow; and grade 3, intensive yellow.  Grade 0 indicates white color.  Yellow plaques of the higher grade are 
regarded more vulnerable as they have higher frequency of plaque disruption.  (From reference #6) 
Fig. 2. Classification of yellow plaques according to their color 
 
The yellow plaque at the culprit lesion is disrupted having thrombus on it.  There are multiple yellow 
plaques in the non-culprit segments both in culprit and non-culprit vessels.  The formation of yellow 
plaques is regarded pan-coronary process.  (From reference #9) 
Fig. 3. Coronary arteries in acute MI patients 
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5. Stent thrombosis and atherosclerosis 
Bare metal stent (BMS) is gradually covered by neointima and the coverage is usually 
completed by 3-6 months after implantation14. Neointima at 3-6 months is generally white 
and its surface is smooth; and stent is not seen buried under neointima. Yellow plaques 
under stent are also covered and buried under the neointima. Neointima becomes thinner 
and rather transparent at about 3 years again15, although its surface is smooth and 
thrombus is not detected on its surface. Therefore, the implantation of BMS stabilizes the 
vulnerable plaques by the formation of thick fibrous neointima over the plaques, which is 
called sealing effect of BMS. It takes about 10 years for the formation of vulnerable 
plaques in the fibrous healthy neointima over BMS leading to its disruption and onset of 
ACS. Very late stent thrombosis (VLST) in the BMS is indeed quite rare especially within a 
few years after implantation. 
On the other hand, neointima formation over drug-eluting stent (DES) is generally very 
poor16, 17; and stent is usually seen through very thin neointima or partly uncovered in the 
majority of cases (Figure 4). The incidence of thrombus at the stented lesion is 
significantly higher in the 1st generation DES (Cypher and Taxus DES) than in BMS. 
Furthermore, the stented lesions become yellow after Cypher DES implantation17, 18, 
suggesting that DES promotes progression of atherosclerosis (Figure 5). However, 
Endeavor DES is known to have larger late loss but have as good neointima formation as 
observed in BMS; and thrombus is rarely detected in this DES. Although the angioscopic 
findings on the newer DES has not been fully clarified, Xience V and Nobori DES appear 
to have as thin neointima as 1st generation DES but have lower incidence of thrombus 
than 1st generation DES. 
The mechanisms for the onset of VLST have not been fully clarified; however, uncovered 
stent strut, uncovered disrupted plaque, new disruption of uncovered yellow plaque, and 
new disruption of newly formed yellow plaque may be the probable thrombogenic 
sources19 that can cause VLST. After BMS and Endeavor DES implantation, thick and 
white fibrous neointima completely covers stent and plaques; and the incidence of VLST 
is known to be very low. However, as the neointima over Xience V and Nobori DES is thin 
and may not reduce the risk of new yellow plaque disruption, we should be careful about 
the incidence of VLST after the implantation of these stents. From the angioscopic point of 
view, Endeavor DES would be the safest DES among the DES examined by angioscopy. 
BMS that has not developed restenosis would be the best condition that should be 
achieved by newly developed DES in the future, i.e. complete coverage by rather thick 
white smooth neointima. 
6. Regression of vulnerable plaques by statin treatment 
Statin treatment is known to reduce both plaque volume evaluated by IVUS and yellow 
color evaluated by angioscopy20, 21. However, it has not been clarified which of plaque 
volume and plaque color is more directly associated with the risk of plaque disruption or 
the risk of ACS. According to the results of TWINS study20, yellow color of plaques 
regressed significantly from baseline to 28 weeks but did not change thereafter until 80 
weeks under atorvastatin treatment; on the other hand, plaque volume decreased gradually 
but significantly from baseline to 28 weeks and to 80 weeks. Early effect of statin treatment 
to reduce the risk of ACS might be reflected by the early regression of yellow color. 
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Various conditions of neointima coverage are observed at 1-year follow-up after DES implantation.  A: 
White and good (grade 2) neointima coverage is observed without thrombus formation.  B: Thin (grade 1) 
neointima coverage is observed without thrombus formation; and the vessel wall under stent is white.  C: 
Thin (grade 1) neointima coverage is observed without thrombus formation; however, the vessel wall 
under stent is yellow.  D: Neointima coverage grade is partly 1 and partly 2.  Both of vessel wall under 
stent and neointima over stent are yellow.  Yellow atherosclerotic neointima is often observed after Cypher 
stent implantation but never after BMS implantation.    E: Uncovered stent strut is observed on the yellow 
disrupted plaque.  Thrombus is detected on the yellow plaque and on the stent strut.  (From reference #17) 
Fig. 4. Angioscopic appearance of DES implanted lesions at follow-up 
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Cypher stent was implanted on a white vessel wall (A).  However, at 1-year follow-up (B), neointima that 
covered the stent was yellow, suggesting the early formation of atherosclerosis in the neointima.  Yellow 
arrow indicates where the stent was implanted.  Red arrow indicates the stent strut.  (From reference #17) 
Fig. 5. Rapid progression of atherosclerosis in the neointima after DES implantation 
7. Investigation of missing factors and hypothesis on the mechanisms of 
ACS onset 
According to the results of PROSPECT trial22, in addition to the presence of TCFA, large 
plaque burden and narrow minimum lumen area were the risk of future coronary event. 
Although ACS is known to occur from angiographically mild to moderate stenosis, findings 
in PROSPECT trial may be consistent with this. Underlying stenosis that can be detected 
only by IVUS and large plaque burden that may cause abrupt progression of stenosis on 
rupturing may be important for the onset of ACS. Presence of relatively severe stenosis 
might be essential for the formation of occlusive thrombus at the disrupted plaque. The 
larger necrotic core might possibly have the higher thrombogenicity; however, there are 
very few investigations on the difference of necrotic core thrombogenicity. Vasoconstriction 
has been speculated to play an important role, although no investigation has ever 
demonstrated its contribution to the onset of ACS. We have reported13 that blood 
thrombogenicity (blood vulnerability index) is significantly and extremely higher in the 
patients with acute MI than in the patients with stable coronary heart disease. This high 
blood thrombogenicity might be either a cause or a result of ACS. However, none of stable 
coronary heart disease patients including those who had silent plaque disruption had that 
high blood vulnerability index. Therefore, silent plaque disruption will never result in the 
extreme increase of blood vulnerability index. Furthermore, ACS patients who were taking 
dual antiplatelet therapy also had high blood vulnerability index, suggesting that dual 
antiplatelet therapy was not adequately effective to prevent this increase of blood 
vulnerability index and thus failed to prevent the onset of ACS. 
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Process of positive feedback and cyclic flow variation might play an important role for the 
onset of ACS: i.e. a plaque disruption causes thrombus formation that increases 
thrombogenicity of blood and more thrombus would be formed; if the occlusive thrombus is 
formed, it may cause cyclic flow variation depending on the severity of stenosis and the 
amount of thrombus formed, which may further increase the thrombogenicity of blood; and 
the thrombus may finally occlude the artery. In this process, the amount of thrombus must 
be influenced by the thrombogenicity of both blood and exposed necrotic core; and the 
severity of stenosis would be determined by the underlying stenosis, the stenosis increased 
by the protrusion of necrotic core on plaque rupturing, and the stenosis caused by 
vasoconstriction that may be induced by thrombus formation. 
It is well known that silent plaque disruption is frequently detected in the patients with 
ACS23, suggesting that plaque disruption and/or thrombogenesis is generally promoted in 
ACS patients (Figure 6). Blood thrombogenicity would be increased in ACS patients as 
mentioned above. Another idea is that coronary vessels generally have inflammation in ACS 
patients, i.e. coronary flu syndrome, which might possibly be the initiation mechanism of 
ACS. 
These mechanisms should be examined more intensively by clinical and basic 
investigations; and blocking some of these steps may be able to prevent the onset of ACS. 
 
 
In a patient with acute MI (culprit lesion at red arrow), a silent plaque disruption (at yellow arrow) was 
detected. The healing process of silently disrupted yellow plaque was observed as the regression of 
yellow color intensity and the disappearance of thrombus by 6 months.  (From reference #23) 
Fig. 6. Silent plaque disruption and its healing in the non-culprit segments in acute MI 
patients 
www.intechopen.com




[1] Ueda Y, Asakura M, Yamaguchi O, Hirayama A, Hori M, Kodama K.  The healing 
process of infarct-related plaques. Insights from 18 months of serial angioscopic 
follow-up.  J Am Coll Cardiol. 2001;38:1916-1922. 
[2] Ueda Y, Asakura M, Hirayama A, Komamura K, Hori M, Kodama K. Intracoronary 
morphology of culprit lesions after reperfusion in acute myocardial infarction: 
serial angioscopic observations. J Am Coll Cardiol. 1996;27:606-610. 
[3] Mizote I, Ueda Y, Ohtani T, Shimizu M, Takeda Y, Oka T, Tsujimoto M, Hirayama A, 
Hori M, Kodama K.. Distal protection improved reperfusion and reduced left 
ventricular dysfunction in patients with acute myocardial infarction who had 
angioscopically defined ruptured plaque. Circulation. 2005;112:1001-1007. 
[4] Sanidas EA, Maehara A, Mintz GS, Kashiyama T, Guo J, Pu J, Shang Y, Claessen B, 
Dangas GD, Leon MB, Moses JW, Stone GW, Ueda Y. Angioscopic and virtual 
histology intravascular ultrasound characteristics of culprit lesion morphology 
underlying coronary artery thrombosis. Am J Cardiol. 2011;107:1285-1290. 
[5] Ueda Y, Ogasawara N, Matsuo K, Hirotani S, Kashiwase K, Hirata A, Nishio M, Nemoto 
T, Wada M, Masumura Y, Kashiyama T, Konishi S, Nakanishi H, Kobayashi Y, 
Akazawa Y, Kodama K.  Acute coronary syndrome: insight from angioscopy.  Circ 
J. 2010;74:411-417. 
[6] Ueda Y, Ohtani T, Shimizu M, Hirayama A, Kodama K.  Assessment of plaque 
vulnerability by angioscopic classification of plaque color.  Am Heart J. 
2004;148:333-335. 
[7] Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, 
Masho T, Kitabata H, Tanaka A, Nakamura N, Mizukoshi M, Tomobuchi Y, 
Akasaka T. Implication of plaque color classification for assessing plaque 
vulnerability: a coronary angioscopy and optical coherence tomography 
investigation. JACC Cardiovasc Interv. 2008;1:74-80. 
[8] Ohtani T, Ueda Y, Mizote I, Oyabu J, Okada K, Hirayama A, Kodama K.  Number of 
yellow plaques detected in a coronary artery is associated with future risk of acute 
coronary syndrome: detection of vulnerable patients by angioscopy.  J Am Coll 
Cardiol. 2006;47:2194-2200. 
[9] Asakura M, Ueda Y, Yamaguchi O, Adachi T, Hirayama A, Hori M, Kodama K.  
Extensive development of vulnerable plaques as a pan-coronary process in patients 
with myocardial infarction: an angioscopic study.  J Am Coll Cardiol. 2001;37:1284-
1288. 
[10] Ueda Y, Hirayama A, Kodama K. Plaque characterization and atherosclerosis 
evaluation by coronary angioscopy. Herz. 2003;28:501-504. 
[11] Masumura Y, Ueda Y, Matsuo K, Akazawa Y, Nishio M, Hirata A, Kashiwase K, 
Nemoto T, Kashiyama T, Wada M, Muller JE, Kodama K. Frequency and location 
of yellow and disrupted coronary plaques in patients as detected by angioscopy. 
Circ J. 2011;75:603-612. 
[12] Muller JE, Tofler GH, Stone PH.  Circadian variation and triggers of onset of acute 
cardiovascular disease.  Circulation 1989;79;733-743. 
[13] Matsuo K, Ueda Y, Nishio M, Hirata A, Asai M, Nemoto T, Kashiwase K, Kodama K.  
Thrombogenic potential of whole blood is higher in patients with acute coronary 
www.intechopen.com
  
Acute Coronary Syndromes 
 
214 
syndrome than in patients with stable coronary diseases.  Thromb Res. 2011, in 
press. 
[14] Ueda Y, Nanto S, Komamura K, Kodama K. Neointimal coverage of stents in human 
coronary arteries observed by angioscopy. J Am Coll Cardiol. 1994;23:341-346. 
[15] Asakura M, Ueda Y, Nanto S, Hirayama A, Adachi T, Kitakaze M, Hori M, Kodama K. 
Remodeling of in-stent neointima, which became thinner and transparent over 3 
years: serial angiographic and angioscopic follow-up. Circulation. 1998;97:2003-206. 
[16] Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic 
evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal 
stent. Am Heart J 2006;152:1168-1174. 
[17] Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, Kashiwase K, Ogasawara N, 
Hirotani S, Kodama K. Atherosclerotic and thrombogenic neointima formed over 
sirolimus drug-eluting stent: an angioscopic study. JACC Cardiovasc Imaging. 
2009;2:616-624. 
[18] Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, 
Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary 
implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314-1322. 
[19] Higo T, Ueda Y, Matsuo K, Nishio M, Hirata A, Asai M, Nemoto T, Murakami A, 
Kashiwase K, Kodama K. Risk of in-stent thrombus formation at one year after 
drug-eluting stent implantation. Thromb Res. 2011, in press. 
[20] Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, 
Yajima J, Nanto S, Takazawa K, Kodama K. Qualitative and quantitative changes in 
coronary plaque associated with atorvastatin therapy. Circ J. 2009;73:718-725. 
[21] Kodama K, Komatsu S, Ueda Y, Takayama T, Yajima J, Nanto S, Matsuoka H, Saito S, 
Hirayama A. Stabilization and regression of coronary plaques treated with 
pitavastatin proven by angioscopy and intravascular ultrasound--the TOGETHAR 
trial. Circ J. 2010;74:1922-1928. 
[22] Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, 
McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys 
PW; PROSPECT Investigators. A prospective natural-history study of coronary 
atherosclerosis.  N Engl J Med. 2011;364:226-35. 
[23] Okada K, Ueda Y, Matsuo K, Nishio M, Hirata A, Kashiwase K, Asai M, Nemoto T, 
Kodama K. Frequency and Healing of Nonculprit Coronary Artery Plaque 




Edited by Dr. Mariano Brizzio
ISBN 978-953-307-827-4
Hard cover, 214 pages
Publisher InTech
Published online 24, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book has been written with the intention of providing an up-to-the minute review of acute coronary
syndromes. Atherosclerotic coronary disease is still a leading cause of death within developed countries and
not surprisingly, is significantly rising in others. Over the past decade the treatment of these syndromes has
changed dramatically. The introduction of novel therapies has impacted the outcomes and surviving rates in
such a way that the medical community need to be up to date almost on a "daily bases". It is hoped that this
book will provide a timely update on acute coronary syndromes and prove to be an invaluable resource for
practitioners seeking new and innovative ways to deliver the best possible care to their patients.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yasunori Ueda (2012). Acute Coronary Syndrome from Angioscopic Viewpoint, Acute Coronary Syndromes,
Dr. Mariano Brizzio (Ed.), ISBN: 978-953-307-827-4, InTech, Available from:
http://www.intechopen.com/books/acute-coronary-syndromes/acute-coronary-syndrome-from-angioscopic-
viewpoint
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
